Literature DB >> 26835275

Improving outcomes in childhood T-cell acute lymphoblastic leukemia: promising results from the Children's Oncology Group incorporating nelarabine into front-line therapy.

Lori Muffly1, Richard A Larson1.   

Abstract

Entities:  

Year:  2012        PMID： 26835275      PMCID： PMC4728878          DOI： 10.3978/j.issn.2224-4336.2012.09.03

Source DB:  PubMed          Journal:  Transl Pediatr        ISSN： 2224-4336


× No keyword cloud information.
  16 in total

1.  Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Kimberly P Dunsmore; Meenakshi Devidas; Stephen B Linda; Michael J Borowitz; Naomi Winick; Stephen P Hunger; William L Carroll; Bruce M Camitta
Journal:  J Clin Oncol       Date:  2012-06-25       Impact factor: 44.544

2.  Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.

Authors:  Wendy Stock; Jeffrey L Johnson; Richard M Stone; Jonathan E Kolitz; Bayard L Powell; Meir Wetzler; Peter Westervelt; Guido Marcucci; Daniel J DeAngelo; James W Vardiman; Diane McDonnell; Krzysztof Mrózek; Clara D Bloomfield; Richard A Larson
Journal:  Cancer       Date:  2012-06-28       Impact factor: 6.860

3.  Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group.

Authors:  Stacey L Berg; Susan M Blaney; Meenakshi Devidas; Tom A Lampkin; Anthony Murgo; Mark Bernstein; Amy Billett; Joanne Kurtzberg; Greg Reaman; Paul Gaynon; James Whitlock; Mark Krailo; Michael B Harris
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

4.  Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies.

Authors:  J Kurtzberg; T J Ernst; M J Keating; V Gandhi; J P Hodge; D F Kisor; J J Lager; C Stephens; J Levin; T Krenitsky; G Elion; B S Mitchell
Journal:  J Clin Oncol       Date:  2005-05-20       Impact factor: 44.544

Review 5.  Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma.

Authors:  Farhad Ravandi; Varsha Gandhi
Journal:  Expert Opin Investig Drugs       Date:  2006-12       Impact factor: 6.206

6.  Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.

Authors:  John M Goldberg; Lewis B Silverman; Donna E Levy; Virginia Kimball Dalton; Richard D Gelber; Leslie Lehmann; Harvey J Cohen; Stephen E Sallan; Barbara L Asselin
Journal:  J Clin Oncol       Date:  2003-10-01       Impact factor: 44.544

Review 7.  Acute lymphoblastic leukaemia.

Authors:  Ching-Hon Pui; Leslie L Robison; A Thomas Look
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

8.  Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.

Authors:  Nita L Seibel; Peter G Steinherz; Harland N Sather; James B Nachman; Cynthia Delaat; Lawrence J Ettinger; David R Freyer; Leonard A Mattano; Caroline A Hastings; Charles M Rubin; Kathy Bertolone; Janet L Franklin; Nyla A Heerema; Torrey L Mitchell; Allan F Pyesmany; Mei K La; Cheryl Edens; Paul S Gaynon
Journal:  Blood       Date:  2007-11-26       Impact factor: 22.113

9.  Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86.

Authors:  A Reiter; M Schrappe; W D Ludwig; W Hiddemann; S Sauter; G Henze; M Zimmermann; F Lampert; W Havers; D Niethammer
Journal:  Blood       Date:  1994-11-01       Impact factor: 22.113

Review 10.  Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.

Authors:  Richard A Larson
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929
View more
  4 in total

1.  Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.

Authors:  Renate De Smedt; Sofie Peirs; Julie Morscio; Filip Matthijssens; Juliette Roels; Lindy Reunes; Beatrice Lintermans; Steven Goossens; Tim Lammens; Nadine Van Roy; Aurore Touzart; Silvia Jenni; Yi-Chien Tsai; Federica Lovisa; Lara Mussolin; Valentina Serafin; Filip Van Nieuwerburgh; Dieter Deforce; Anne Uyttebroeck; Thomas Tousseyn; Birgit Burkhardt; Wolfram Klapper; Barbara De Moerloose; Yves Benoit; Elizabeth Macintyre; Jean-Pierre Bourquin; Giuseppe Basso; Benedetta Accordi; Beat Bornhauser; Jules Meijerink; Peter Vandenberghe; Pieter Van Vlierberghe
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941

2.  The rare translocation t(14;21)(q11;q22) detected in a Moroccan patient with T-cell acute lymphoblastic leukemia.

Authors:  Z Takki Chebihi; A Belkhayat; E Chadli; L Hessissen; M El Khorassani; M El Kababri; A Kili; M Khattab; Y Bakri; N Dakka
Journal:  Leuk Res Rep       Date:  2018-11-22

3.  High-dose methotrexate vs. Capizzi methotrexate for the treatment of childhood T-cell acute lymphoblastic leukemia.

Authors:  Wasil Jastaniah; Naglla Elimam; Khalid Abdalla; Aeshah A AlAzmi; Mohammed Aseeri; Sami Felimban
Journal:  Leuk Res Rep       Date:  2018-10-09

4.  Progress against childhood and adolescent acute lymphoblastic leukaemia in the Netherlands, 1990-2015.

Authors:  Henrike E Karim-Kos; Rob Pieters; Ardine M J Reedijk; Jan Willem W Coebergh; Hester A de Groot-Kruseman; Inge M van der Sluis; Leontien C Kremer
Journal:  Leukemia       Date:  2020-08-21       Impact factor: 11.528
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.